Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUTICASONE PROPIONATE

All products: general benefit

Other products in the same Health Canada class (R03BA) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Qvar): general benefit
  • Budesonide (Pulmicort Nebuamp): general benefit, Limited Use 260, 261, 262, 263, 264
  • Ciclesonide (Alvesco): general benefit
  • Fluticasone furoate (Arnuity Ellipta): general benefit
  • Mometasone furoate (Asmanex Twisthaler): general benefit

Flovent HFA · DIN 02244291 · 50mcg/Metered Dose · inhaler, 120 doses

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Flovent HFA (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Flovent HFA · DIN 02244291 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2002-07-29 Health Canada: Marketed since 2001-12-20 · brand FLOVENT HFA · ATC R03BA05 FLUTICASONE · form Aerosol (metered-dose) · route Inhalation, Oral · ingredients FLUTICASONE PROPIONATE 50 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $14.2080 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68258 · Verify on the e-Formulary ↗ (DIN 02244291)

Source record
DIN 02244291: Flovent HFA Raw flags: sec3=Y Item: 680400086; group id 711; item number 1752; lccId None; manufacturer id GSK Source form: Inh-120 Dose Pk; strength: 50mcg/Metered Dose Recorded listing: General benefit Source prices (unrounded): $34.3900; ministry $14.2080 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244291 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68258
Interchangeable products
Apo-Fluticasone HFA · DIN 02528428 · $14.2080 PMS-Fluticasone HFA · DIN 02503115 · $14.2080
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

MOMETASONE FUROATE

· 3 products · General benefit · strengths: 400mcg/Metered Dose, 200mcg/Metered Dose · Pd Inh-30 Dose Pk, Pd Inh-60 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: steroid-responsive bronchial asthma
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CICLESONIDE, FLUTICASONE FUROATE CICLESONIDE · General benefit INDICATIONS AND CLINICAL USE ALVESCO (ciclesonide) is indicated for:  prophylactic management of steroid-responsive bronchial asthma in adults, adolescents and children 6 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00060608.PDF; date March 30, 2021; DIN 02285606; fetched 2026-09-10 Product monograph FLUTICASONE FUROATE · General benefit 1 INDICATIONS ARNUITY ELLIPTA (fluticasone furoate) is indicated for the once-daily maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older. PM: https://pdf.hres.ca/dpd_pm/00072514.PDF; date September 21, 2015; DIN 02446561; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS FLOVENT (fluticasone propionate) is indicated for:  the prophylactic management of steroid-responsive bronchial asthma in adults and children (12 months of age or older). For children, this includes patients not controlled on currently available prophylactic medication. FLOVENT is not indicated for the relief of acute bronchospasm (see 7 WARNINGS AND PRECAUTIONS, general). 1.1 Pediatrics Pediatrics (12 months of age and older): FLOVENT DISKUS is indicated for any child 4 years of age and older, and FLOVENT HFA inhalation aerosol is indicated for children 12 months of age and above who require prophylactic medication, including patients not controlled on currently available prophylactic medication. At present there are insufficient clinical data to recommend the use of FLOVENT DISKUS in children younger than 4 years and the use of FLOVENT HFA inhalation aerosol in children younger than 12 months. 1.2 Geriatrics There is no need to adjust the dose in elderly patients. https://pdf.hres.ca/dpd_pm/00060119.PDF PM date: March 1, 2021 Source product: FLOVENT DISKUS; DIN 02237246; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.